Press Release

Combination Anti-diabetes Drugs Market Share, Size 2019-2024 | Industry Analysis, Overview of Market Dynamics, Top Key Players, and Regional Forecast to 2024


The “Combination Anti-diabetes Drugs Market” report 2019 provides information for market players, stakeholders, investors, and business strategists to achieve a leading position the market. It maintains the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Combination Anti-diabetes Drugs market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Combination Anti-diabetes Drugs market is provided in detail in the report.

Get a Sample Copy of the Report –  

Combination Anti-diabetes Drugs Market Covers Key Players:

  • Novo Nordisk
  • Merck
  • Sanofi

    Market Overview:

  • The diabetes population in the world is increasing continuously. This trend is mainly due to the changing lifestyle of the majority of the population. Most of the population have unhealthy lifestyles. The change in lifestyle is due to the economic and industrial development in recent times in most of the countries. For most of the population, sedentary lifestyles and seemingly endless fast-food options have replaced the traditional ways of work, travel, and cuisine, making way for the increase of diseases, such as diabetic. WHO projects that diabetes will be the seventh leading cause of death in 2030. In 2014, 8.5% of adults aged 18 years and older had diabetes. In 2015, diabetes was the direct cause of 1.6 million deaths and in 2012, high blood glucose was the cause of another 2.2 million deaths. It expected that this number would keep increasing shortly.

    Report Highlights:

    • The report provides a detailed analysis on current and future market trends to identify the investment opportunities
    • Market forecasts till 2024, using estimated market values as the base numbers
    • Key market trends across the business segments, Regions and Countries
    • Key developments and strategies observed in the market
    • Market Dynamics such as Drivers, Restraints, Opportunities and other trends
    • In-depth company profiles of key players and upcoming prominent players
    • Growth prospects among the emerging nations through 2024
    • Combination Anti-diabetes Drugs Market opportunities and recommendations for new investments

    For More Information or Query or Customization Before Buying, Visit at

    Scope of the Report:

  • The market is segmented by category (oral combinations and insulin combinations), by segment (Janumet, Ryzodeg, Xultophy, and NovoMix), and Geography

    Key Market Trends:

    Diabetes Patients Need More than One Drug to Control their Glycemic Level

    – Diabetes is considered to be a rich man disease, not only because of the cost of the drugs but also because of the number of medicines one must consume. Over the years, a large number of drug manufacturers has introduced combination drugs, thus making it more convenient for consumers.
    – These combination drugs have two or more active pharmaceutical ingredients, thus serving the purpose of two anti-diabetic drugs. The manufacturers have in the past started with essential oral medicines, such as Janumet and now have developed advanced insulin combinations, such as Ryzodeg and Xultophy.
    – Consumer preference for these drugs has increased considerably over time. The combination drugs market was valued 4.01 billion in 2018 and is expected to witness a CAGR of 10%, during the forecast period.

    Ryzodeg is Expected to Record a CAGR of 23%

    – Ryzodeg is a combination of ultra-long-acting insulin degludec (basal) and rapid-acting prandial insulin aspart (bolus).
    – At present, consumers need to use both the basal and bolus insulin to manage their glucose levels, but Ryzodeg acts as a perfect substitute to bolus and basal insulin.
    – Ryzodeg serves the purpose of the two insulin’s, making it more convenient for consumers. Due to its unique combination, the market for the drug is expected to grow exponentially shortly.
    – Ryzodeg is available in close to 18 countries, but Novo Nordisk plans to increase its marketing and sales resources to improve the availability of the drug inadvertently.

    Purchase this Report (Price 5000 USD for single user license) –

    Detailed TOC of Combination Anti-diabetes Drugs Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5.1 BY Drug
    5.1.1 Combination Drugs Insulin Combinations NovoMix (Biphasic Insulin Aspart) Ryzodeg (Insulin Degludec and Insulin Aspart) Xultophy (Insulin Degludec and Liraglutide) Oral Combination Janumet (Sitagliptin and Metformin HCl)
    5.2 Geography
    5.2.1 North America United States (Value and Volume 2012-2024) Canada (Value and Volume 2012-2024) Rest of North America (Value and Volume 2012-2024)
    5.2.2 Europe France (Value and Volume 2012-2024) Germany (Value and Volume 2012-2024) Italy (Value and Volume 2012-2024) Spain (Value and Volume 2012-2024) United Kingdom (Value and Volume 2012-2024) Russia (Value and Volume 2012-2024) Rest of Europe (Value and Volume 2012-2024)
    5.2.3 Latin America Mexico (Value and Volume 2012-2024) Brazil (Value and Volume 2012-2024) Rest of Latin America (Value and Volume 2012-2024)
    5.2.4 Asia – Pacific Australia (Value and Volume 2012 – 2024) China (Value and Volume 2012-2024) India (Value and Volume 2012-2024) Indonesia (Value and Volume 2012-2024) Japan (Value and Volume 2012-2024) Malaysia (Value and Volume 2012-2024) Philippines (Value and Volume 2012-2024) South Korea (Value and Volume 2012-2024) Thailand (Value and Volume 2012-2024) Vietnam (Value and Volume 2012-2024) Rest of Asia – Pacific (Value and Volume 2012-2024)
    5.2.5 Middle East & Africa Saudi Arabia (Value and Volume 2012-2024) Iran (Value and Volume 2012-2024) Egypt (Value and Volume 2012-2024) Oman (Value and Volume 2012-2024) South Africa (Value and Volume 2012-2024) Rest of Middle East & Africa (Value and Volume 2012-2024)

    6.1 Type-1 Diabetes population (2012-2024)
    6.2 Type-2 Diabetes population (2012-2024)

    7.1 Company Profiles
    7.1.1 Novo Nordisk
    7.1.2 Merck
    7.1.3 Sanofi



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global WiFi Home Router Market Size & Share 2019 By Sales Revenue, Future Demands, Growth Factors, Emerging Trends, Competitive Landscape and Forecast to 2024

    Global Soil Compaction Tester Market Share, Size 2019 Movements by Trend Analysis, Progression Status, Revenue Expectation to 2024 | Research Report by Industry Research.Biz

    Global Adhesive & Sealant Market Size & share 2019: Subdivision by, Challenges and Key Findings Forecast 2025

    Global Cardamom Oil Market Size 2019: Research Methodology, Top Manufactures and Market Size Estimate 2025

  • Alfredoo Epps

    Alfredo Epps is a finance expert heading the petroleum column. He joined the group last year as an associate writer. But his thorough research skills and ability to seamlessly putting numerical data into words helped him get a senior position. Apart from a column head, Alfredo is a dancer and a violinist.

    Related Articles

    Leave a Reply

    Your email address will not be published. Required fields are marked *